| Size | Price | Stock | Qty |
|---|---|---|---|
| 100U |
|
||
| 1KU |
|
||
| Other Sizes |
| Targets |
Oxalate Oxidase targets oxalic acid as its substrate, catalyzing its oxidative cleavage. The enzyme's activity is dependent on Mn2+ as a cofactor. The reaction produces hydrogen peroxide and carbon dioxide. It is not a classical pharmacological target but an enzyme used in biocatalysis and diagnostic applications.
|
|---|---|
| ln Vitro |
In vitro, Oxalate Oxidase exhibits enzymatic activity by oxidizing oxalic acid. One unit of activity is defined as the amount of enzyme required to oxidize 1 micromole of oxalate per minute at pH 5.0 and 37°C. Specific activity is typically 5.9 U/mg protein. The enzyme is stable when stored at -20°C.
|
| ln Vivo |
In vivo activity data for Oxalate Oxidase are not applicable as it is an enzyme used in industrial and diagnostic applications rather than as a therapeutic agent. It is not administered to living organisms for therapeutic purposes.
|
| Enzyme Assay |
The non-cellular assay for Oxalate Oxidase involves incubating the enzyme with oxalic acid substrate in an appropriate buffer at pH 5.0 and 37°C. The reaction produces hydrogen peroxide, which can be measured colorimetrically using a peroxidase-coupled assay with a chromogenic substrate (e.g., ABTS or o-dianisidine). Activity is expressed in units per milligram of protein.
|
| Cell Assay |
In vitro cell-based assays are not applicable for Oxalate Oxidase as it is an enzyme used in industrial and diagnostic applications. It is not used in cell-based pharmacological studies.
|
| Animal Protocol |
In vivo animal study protocols are not applicable for Oxalate Oxidase as it is not a therapeutic agent. No animal studies have been reported for therapeutic use.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for Oxalate Oxidase as it is not a therapeutic agent administered to living organisms. The enzyme is used in industrial processes and diagnostic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for Oxalate Oxidase are not extensively reported. As an enzyme from natural sources, it is generally considered safe for its intended applications. Standard safety precautions should be observed during handling.
|
| References |
|
| Additional Infomation |
Oxalate Oxidase (EC 1.2.3.4) is a manganese-dependent enzyme that catalyzes the oxidation of oxalic acid. It is found in plants and microorganisms and is used in wastewater treatment and diagnostic applications. It is not a therapeutic drug and has no clinical trial or marketing authorization status.
|
| Molecular Formula |
C59H62F2N14O4
|
|---|---|
| Molecular Weight |
1069.21179819107
|
| Exact Mass |
1068.505
|
| CAS # |
9031-79-2
|
| PubChem CID |
168010059
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
79
|
| Complexity |
1750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=CC=CC(=C1)OC1C=CC(=CC=1)C1C2=C(N)N=CN=C2N(C2CN(C(C=CCN(C)C3CC3)=O)CC2)N=1.FC1=CC=CC(=C1)OC1C=CC(=CC=1)C1C2=C(N)N=CN=C2N(C2CN(C(C=CCN(C)C3CCC3)=O)CC2)N=1
|
| InChi Key |
PPYSQMADMKLTCU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H32FN7O2.C29H30FN7O2/c1-36(22-6-3-7-22)15-4-9-26(39)37-16-14-23(18-37)38-30-27(29(32)33-19-34-30)28(35-38)20-10-12-24(13-11-20)40-25-8-2-5-21(31)17-25;1-35(21-9-10-21)14-3-6-25(38)36-15-13-22(17-36)37-29-26(28(31)32-18-33-29)27(34-37)19-7-11-23(12-8-19)39-24-5-2-4-20(30)16-24/h2,4-5,8-13,17,19,22-23H,3,6-7,14-16,18H2,1H3,(H2,32,33,34);2-8,11-12,16,18,21-22H,9-10,13-15,17H2,1H3,(H2,31,32,33)
|
| Chemical Name |
1-[3-[4-amino-3-[4-(3-fluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-4-[cyclobutyl(methyl)amino]but-2-en-1-one;1-[3-[4-amino-3-[4-(3-fluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-4-[cyclopropyl(methyl)amino]but-2-en-1-one
|
| Synonyms |
Oxalate oxidase
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9353 mL | 4.6763 mL | 9.3527 mL | |
| 5 mM | 0.1871 mL | 0.9353 mL | 1.8705 mL | |
| 10 mM | 0.0935 mL | 0.4676 mL | 0.9353 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
